Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.
(2018) Biology of Blood and Marrow Transplantation — Vol. 24, n° 3, p. 507-513 (2018)
Files
2018_Garderet_Biol_Blood_Marrow_Transplant.pdf
Open Access - Adobe PDF
- 663.93 KB
Details
- Authors
- Abstract
- The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.
- Affiliations
Citations
Garderet, L., Ziagkos, D., van Biezen, A., Iacobelli, S., Finke, J., Maertens, J., Volin, L., Ljungman, P., Chevallier, P., Passweg, J., Schaap, N., Beelen, D., Nagler, A., Blaise, D., Poire, X., Yakoub-Agha, I., Lenhoff, S., Craddock, C., Schots, R., et al. (2018). Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. Biology of Blood and Marrow Transplantation, 24(3), 507-513. https://doi.org/10.1016/j.bbmt.2017.11.017 (Original work published 2018)